Table 4 -.
Multivariable analyses assessing the association between various patient-, disease-, and transplant-related factors and clinical outcomes
| Measure | OS | RFS | RI | NRM | aGVHD* | cGVHD | CMV |
|---|---|---|---|---|---|---|---|
| Age (years) | 1.00 (0.99, 1.01) | 1.00 (0.99, 1.01) | 0.99 (0.97, 1.00) | 1.02 (1.00, 1.04) | 0.99 (0.96, 1.02) | 1.00 (0.98, 1.01) | 0.99 (0.96, 1.02) |
| Diagnosis (AML/MDS vs. ALL) | 0.84 (0.54, 1.32) | 0.93 (0.60, 1.45) | 0.83 (0.47, 1.44) | 1.49 (0.65, 3.40) | 0.78 (0.23, 2.72) | 1.41 (0.82, 2.44) | 0.59 (0.16, 2.18) |
| Matched donor (yes vs. no) | 0.84 (0.61, 1.15) | 0.80 (0.59, 1.10) | 1.03 (0.69, 1.54) | 0.59 (0.37, 0.95) | 0.48 (0.19, 1.19) | 0.86 (0.62, 1.21) | 0.40 (0.17, 0.96) |
| Related donor (yes vs. no) | 0.79 (0.54, 1.15) | 0.72 (0.49, 1.05) | 0.95 (0.56, 1.61) | 0.60 (0.34, 1.07) | 0.49 (0.17, 1.45) | 0.74 (0.44, 1.24) | 1.18 (0.39, 3.60) |
| CR at BMT (yes vs. no) | 0.38 (0.29, 0.50) | 0.42 (0.32, 0.55) | 0.37 (0.26, 0.52) | 0.91 (0.59, 1.39) | 0.87 (0.41, 1.86) | 0.97 (0.72, 1.30) | 0.55 (0.25, 1.22) |
| Preparatory regimen (TBI vs. Other) | 0.81 (0.49, 1.33) | 0.89 (0.54, 1.46) | 1.15 (0.59, 2.24) | 0.95 (0.40, 2.26) | 1.55 (0.26, 9.22) | 1.03 (0.55, 1.92) | 0.09 (0.00, 1.84) |
| Preparatory regimen (Busulfan vs. Other) | 0.71 (0.54, 0.94) | 0.69 (0.52, 0.91) | 0.84 (0.59, 1.19) | 0.68 (0.43, 1.08) | 3.45 (1.03, 11.56) | 0.87 (0.62, 1.23) | 0.91 (0.39, 2.16) |
| ATG or alemtuzumab (yes vs. no) | 0.79 (0.55, 1.14) | 0.91 (0.63, 1.32) | 1.40 (0.84, 2.33) | 0.54 (0.31, 0.95) | 0.46 (0.15, 1.42) | 0.84 (0.51, 1.38) | 1.74 (0.49, 6.18) |
| Post-BMT Cyclophos (yes vs. no) | 0.82 (0.49, 1.39) | 1.01 (0.61, 1.65) | 1.27 (0.69, 2.32) | 0.56 (0.23, 1.37) | 2.01 (0.56, 7.21) | 0.71 (0.38, 1.32) | 1.34 (0.36, 4.98) |
| ALC60 group (>300 vs. ≤300/μL) | 0.46 (0.36, 0.60) | 0.56 (0.43, 0.72) | 1.68 (1.12, 2.51) | 0.21 (0.14, 0.31) | 0.37 (0.15, 0.92) | 0.79 (0.58, 1.08) | 1.07 (0.46, 2.50) |
aGVHD: acute graft-versus-host disease, ALC60: Absolute lymphocyte count on post-BMT day 60, ALL: Acute lymphoid leukemia, AML: Acute myeloid leukemia, ATG: Anti-thymocyte globulin, BMT: Bone marrow transplantation, cGVHD: chronic graft-versus-host diseae, CMV: Cytomegalovirus, CR: Complete remission, MDS: Myelodysplastic syndrome, NRM: Non-relapse mortality, OS: Oveall survival, RFS: Relapse-free survival, RI: Relapse incidence, TBI: Total body irradiation
*:
aGVHD developed prior to day 60 were excluded from the analyses